The Kaposi’s Sarcoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Kaposi’s Sarcoma: An Overview
Kaposi’s Sarcoma (KS) is a multicentric vascular tumor originating in the endothelial cells that line blood vessels and lymphatic vessels. KS is caused when tiny blood vessels develop below the surface of the skin, in the mouth, nose, eyes, or other parts of the body, such as the lymph nodes or lungs. Individuals with weak immune systems have a high risk of Kaposi’s Sarcoma. The lesions of Kaposi’s Sarcoma typically appear as painless purplish spots on the feet, legs, face, genital area, mouth, or lymph nodes. In severe Kaposi’s Sarcoma, lesions may develop in the lungs and digestive tract.
The treatment of Kaposi’s Sarcoma consists of antiretroviral therapies, radiation therapy, chemotherapy drugs such as Doxorubicin (Adriamycin, Doxil), Paclitaxel (Taxol), Vinblastine (Velban), etc. and several biologic therapies to boost the immune system.
Kaposi’s Sarcoma Market Key Facts
-
As per the study conducted by Takahashi et al., 2017, Kaposi’s Sarcoma (KS) is extremely rare in Japan but highly endemic in Okinawa, especially in Miyako Islands. The age-adjusted incidence rate was 0.87/105 per year for the Miyako Islands and 0.056/105 per year for the rest of Okinawa.
- All forms of Kaposi’s Sarcoma (KS) are more common in men than in women.
Kaposi’s Sarcoma market size is anticipated to increase during the study period owing to the rise in the number of prevalent cases in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Kaposi’s Sarcoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Kaposi’s Sarcoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Kaposi’s Sarcoma Epidemiology
The epidemiology section covers insights about the historical and current Kaposi’s Sarcoma patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Kaposi’s Sarcoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Kaposi’s Sarcoma market or expected to get launched in the market during the study period. The analysis covers Kaposi’s Sarcoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Kaposi’s Sarcoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/kaposis-sarcoma-market
Kaposi’s Sarcoma Therapeutics Analysis
The main forms of treatment for Kaposi’s Sarcoma are Antiretroviral Therapy, Surgery, Photodynamic Therapy, Radiation Therapy, therapies using medications such as Chemotherapy, Topical medications, Targeted Therapy, and Immunotherapy. The current Kaposi’s Sarcoma pipeline does not hold many significant products, it has very few products that are being developed by certain key players.
Kaposi’s Sarcoma Companies:
-
Vasgene Therapeutics, Inc.
-
Bristol-Myers Squibb
-
Navidea Biopharmaceuticals
-
Xencor, Inc.
And many others.
Kaposi’s Sarcoma Therapies covered in the report include:
-
Tc 99m Tilmanocept
-
XmAb13676
-
Nivolumab and Ipilimumab
-
sEphB4-HSA
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies: https://www.delveinsight.com/sample-request/kaposis-sarcoma-market
Table of Content
1. Key Insights
2. Executive Summary
3. Kaposi’s Sarcoma Competitive Intelligence Analysis
4. Kaposi’s Sarcoma Market Overview at a Glance
5. Kaposi’s Sarcoma Disease Background and Overview
6. Kaposi’s Sarcoma Patient Journey
7. Kaposi’s Sarcoma Epidemiology and Patient Population
8. Kaposi’s Sarcoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Kaposi’s Sarcoma Unmet Needs
10. Key Endpoints of Kaposi’s Sarcoma Treatment
11. Kaposi’s Sarcoma Marketed Products
12. Kaposi’s Sarcoma Emerging Therapies
13. Kaposi’s Sarcoma Seven Major Market Analysis
14. Attribute Analysis
15. Kaposi’s Sarcoma Market Outlook (7 major markets)
16. Kaposi’s Sarcoma Access and Reimbursement Overview
17. KOL Views on the Kaposi’s Sarcoma Market.
18. Kaposi’s Sarcoma Market Drivers
19. Kaposi’s Sarcoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/kaposis-sarcoma-market
Other Latest Healthcare Report by DelveInsight
Injectable Drug Delivery Devices Market
The Global Injectable Drug Delivery Devices Market is expected to reach USD 33.37 billion by 2026. Some of the key MedTech companies such Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and others, are actively working in the Injectable Drug Delivery Devices Market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/